Literature DB >> 16019506

Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma.

Youli Zu1, Seth M Steinberg, Elias Campo, Christine P Hans, Dennis D Weisenburger, Rita M Braziel, Jan Delabie, Randy D Gascoyne, Konrad Muller-Hermlink, Stefania Pittaluga, Mark Raffeld, Wing C Chan, Elaine S Jaffe.   

Abstract

Tissue microarrays (TMAs) show concordance with whole tissue sections in the immunohistochemical evaluation of tumor cells. However, potential inter-institutional variability among observers and immunohistochemical staining methods has not been fully addressed. We selected 21 cases of diffuse large B-cell lymphoma (DLBCL) to process for TMAs. Immunohistochemical stains were performed in 3 laboratories, and reviewed independently by 3 hematopathologists at the 3 institutions. Stains were scored on a 4-point scale. Statistical analyses of variation in the scoring among observers and among different institutions' stains were performed. Stains for CD3, CD10, CD20, BCL-2, BCL-6, MIB-1, and FOX-P1 revealed little variation among observers, with an average 51-82% complete agreement and 82-100% agreement +/- 1 numerical score. The rate of concordance when evaluating most stains performed in different laboratories was also relatively good, with an average of 55-72% complete agreement and 70-97% agreement +/- 1 score. However, scoring of MUM-1 and p53 stains showed wider variation, with an average of only 37 and 30% complete agreement among observers, and 11 and 45% agreement when stains from different institutions were examined. Further statistical analyses were performed to compare the observers' scoring of their own institution's stains (self-review) vs. observers' scoring of other institutions' stains (non-self). The agreement rate for the p53 stain was significantly higher when based on self-review (average 58% complete agreement) compared with an agreement rate of only 10.5% when based on a review of stains performed in another laboratory, non-self review, P < 0.01. This difference in the self- vs. non-self review was not seen when data for MUM-1 were analysed. In conclusion, most phenotypic markers used in the analysis of DLBCL can be evaluated in TMAs with adequate agreement among observers and laboratories. These include CD3, CD20, CD10, BCL-2, BCL-6, MIB-1, and FOX-P1. However, some markers, such as p53 and MUM-1, are more prone to inter-institutional variation. Variations in interpretation can be partially overcome by self-adjusted/adapt tendency, as seen with p53. Especially with newly developed markers, such as MUM-1, the development of standardized techniques for staining and interpretation is critical to reduce inter-observer variability.

Entities:  

Mesh:

Year:  2005        PMID: 16019506     DOI: 10.1080/10428190500051844

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  15 in total

Review 1.  Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification.

Authors:  Elaine S Jaffe; Stefania Pittaluga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.

Authors:  J Iqbal; T C Greiner; K Patel; B J Dave; L Smith; J Ji; G Wright; W G Sanger; D L Pickering; S Jain; D E Horsman; Y Shen; K Fu; D D Weisenburger; C P Hans; E Campo; R D Gascoyne; A Rosenwald; E S Jaffe; J Delabie; L Rimsza; G Ott; H K Müller-Hermelink; J M Connors; J M Vose; T McKeithan; L M Staudt; W C Chan
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

Review 3.  Virtual microscopy as an enabler of automated/quantitative assessment of protein expression in TMAs.

Authors:  Catherine Conway; Lynne Dobson; Anthony O'Grady; Elaine Kay; Sean Costello; Daniel O'Shea
Journal:  Histochem Cell Biol       Date:  2008-08-05       Impact factor: 4.304

4.  Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.

Authors:  Ana Borovecki; Petra Korać; Marin Nola; Davor Ivanković; Branimir Jaksić; Mara Dominis
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

5.  Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure.

Authors:  Marylène Lejeune; Joaquín Jaén; Lluis Pons; Carlos López; Maria-Teresa Salvadó; Ramón Bosch; Marcial García; Patricia Escrivà; Jordi Baucells; Xavier Cugat; Tomás Alvaro
Journal:  J Anat       Date:  2008-06       Impact factor: 2.610

Review 6.  The histological classification of diffuse large B-cell lymphomas.

Authors:  Yi Xie; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Hematol       Date:  2015-01-17       Impact factor: 3.851

7.  Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma.

Authors:  D Azambuja; Y Natkunam; I Biasoli; I S Lossos; M W Anderson; J C Morais; N Spector
Journal:  Ann Oncol       Date:  2011-05-20       Impact factor: 32.976

Review 8.  The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification.

Authors:  Madhu P Menon; Stefania Pittaluga; Elaine S Jaffe
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

9.  Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.

Authors:  Eri Ishikawa; Masanao Nakamura; Kazuyuki Shimada; Tsutomu Tanaka; Akira Satou; Kei Kohno; Ayako Sakakibara; Kazuhiro Furukawa; Takeshi Yamamura; Ryoji Miyahara; Shigeo Nakamura; Seiichi Kato; Mitsuhiro Fujishiro
Journal:  J Gastroenterol       Date:  2019-09-06       Impact factor: 7.527

10.  Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer.

Authors:  Jenny Permuth-Wey; David Boulware; Nikola Valkov; Sandra Livingston; Santo Nicosia; Ji-Hyun Lee; Rebecca Sutphen; Joellen Schildkraut; Steven Narod; Alex Parker; Domenico Coppola; Thomas Sellers; Tuya Pal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.